Prescient Therapeutics Ltd
ASX:PTX ISIN:AU000000PTX3
Prescient Therapeutics Limited is a clinical-stage oncology company. The Company's principal activities include in-licensing of intellectual property; the preparation for and conduct of clinical trials relating to the Company's products; business development associated with the promotion of its technologies and products, and business development associated with developing collaborative, partnership relationships and corporate transactions.
View in Other Languages
News
Australian Market Report of February 14, 2011 includes: Black Fire Minerals Limited (ASX:BFE) is to acquire 100% of the advanced Pilot Mountain Tungsten-Copper Project in Nevada, USA; Virax Holdings Limited (ASX:VHL) is to develop a novel skin cancer product; Southern Cross Goldfields Limited (ASX:SXG) discovered near-surface high-grade gold deposits in Western Australia; Prosperity Resources Limited (ASX:PSP) commenced gold drilling in Indonesia.
Virax Holdings Limited (ASX: VHL) - Commencement of Phase II US trials - Dr David Beames, CEO; Boardroomradio is pleased to announce that Virax Holdings Limited (ASX: VHL) has published an audio file.
The August 2006 edition of our Health & Life Science Quarterly Blue Book profiles niche life sciences companies, with a focus on company strategies, key projects and significant milestones.
###
133,990 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 13) (Last 30 Days: 43) (Since Published: 12929)
